The Personalized Virology Initiative (PVI) is an interdisciplinary clinical research task force operating at the cross section of research and clinical work here at the Mount Sinai Health System. PVI seeks to integrate the opportunities to participate in observational studies to patients and clinical providers at the Mount Sinai Health System. Ongoing projects include SARS-CoV-2 antibody serosurveillance and monitoring in diverse patient populations and health care workers. This type of research helps to better understanding of the human immune response mounted to both SARS-CoV-2 natural infection and the long haul of COVID-19 as well as observing responses to the vaccines for SARS-CoV-2. Our team not only studies SARS-CoV-2 but all viral infections, prominently working with HIV/AIDS and Influenza. Our collaborations and research units operate across Manhattan and we are active at 3 Mount Sinai Health System Hospitals. We have enrolled over 2000 research participants and collected over 8,500 samples across our study portfolio.